

# Global Anaplastic Lymphoma Kinase Inhibitors Market Growth 2024-2030

<https://marketpublishers.com/r/GA005843383EN.html>

Date: March 2024

Pages: 116

Price: US\$ 3,660.00 (Single User License)

ID: GA005843383EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Anaplastic Lymphoma Kinase Inhibitors market size was valued at US\$ million in 2023. With growing demand in downstream market, the Anaplastic Lymphoma Kinase Inhibitors is forecast to a readjusted size of US\$ million by 2030 with a CAGR of % during review period.

The research report highlights the growth potential of the global Anaplastic Lymphoma Kinase Inhibitors market. Anaplastic Lymphoma Kinase Inhibitors are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Anaplastic Lymphoma Kinase Inhibitors. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Anaplastic Lymphoma Kinase Inhibitors market.

ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[]

### Key Features:

The report on Anaplastic Lymphoma Kinase Inhibitors market reflects various aspects and provide valuable insights into the industry.

**Market Size and Growth:** The research report provide an overview of the current size and growth of the Anaplastic Lymphoma Kinase Inhibitors market. It may include

historical data, market segmentation by Type (e.g., Crizotinib, Ceritinib), and regional breakdowns.

**Market Drivers and Challenges:** The report can identify and analyse the factors driving the growth of the Anaplastic Lymphoma Kinase Inhibitors market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

**Competitive Landscape:** The research report provides analysis of the competitive landscape within the Anaplastic Lymphoma Kinase Inhibitors market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

**Technological Developments:** The research report can delve into the latest technological developments in the Anaplastic Lymphoma Kinase Inhibitors industry. This include advancements in Anaplastic Lymphoma Kinase Inhibitors technology, Anaplastic Lymphoma Kinase Inhibitors new entrants, Anaplastic Lymphoma Kinase Inhibitors new investment, and other innovations that are shaping the future of Anaplastic Lymphoma Kinase Inhibitors.

**Downstream Procumbent Preference:** The report can shed light on customer procumbent behaviour and adoption trends in the Anaplastic Lymphoma Kinase Inhibitors market. It includes factors influencing customer ' purchasing decisions, preferences for Anaplastic Lymphoma Kinase Inhibitors product.

**Government Policies and Incentives:** The research report analyse the impact of government policies and incentives on the Anaplastic Lymphoma Kinase Inhibitors market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Anaplastic Lymphoma Kinase Inhibitors market. The report also evaluates the effectiveness of these policies in driving market growth.

**Environmental Impact and Sustainability:** The research report assess the environmental impact and sustainability aspects of the Anaplastic Lymphoma Kinase Inhibitors market.

**Market Forecasts and Future Outlook:** Based on the analysis conducted, the research report provide market forecasts and outlook for the Anaplastic Lymphoma Kinase Inhibitors industry. This includes projections of market size, growth rates, regional

trends, and predictions on technological advancements and policy developments.

**Recommendations and Opportunities:** The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Anaplastic Lymphoma Kinase Inhibitors market.

#### Market Segmentation:

Anaplastic Lymphoma Kinase Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

#### Segmentation by type

Crizotinib

Ceritinib

Alectinib Hydrochloride

#### Segmentation by application

NSCLC

Breast Cancer

Colorectal Cancer

Neuroblastoma

Ovarian Cancer

Others

This report also splits the market by region:

### Americas

United States

Canada

Mexico

Brazil

### APAC

China

Japan

Korea

Southeast Asia

India

Australia

### Europe

Germany

France

UK

Italy

Russia

### Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Betta Pharmaceuticals Co., Ltd.

Crtierium, Inc.

F.Hoffman-La Roche Ltd.

Helsinn Therapeutics

Novartis AG.

Oncoethix GmbH

Pfizer, Inc.

Takeda Pharmaceutical Co., Ltd.

Xcovery Holding Company, LLC

Tesaro, Inc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anaplastic Lymphoma Kinase Inhibitors market?

What factors are driving Anaplastic Lymphoma Kinase Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anaplastic Lymphoma Kinase Inhibitors market opportunities vary by end market size?

How does Anaplastic Lymphoma Kinase Inhibitors break out type, application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Annual Sales 2019-2030
  - 2.1.2 World Current & Future Analysis for Anaplastic Lymphoma Kinase Inhibitors by Geographic Region, 2019, 2023 & 2030
  - 2.1.3 World Current & Future Analysis for Anaplastic Lymphoma Kinase Inhibitors by Country/Region, 2019, 2023 & 2030
- 2.2 Anaplastic Lymphoma Kinase Inhibitors Segment by Type
  - 2.2.1 Crizotinib
  - 2.2.2 Ceritinib
  - 2.2.3 Alectinib Hydrochloride
- 2.3 Anaplastic Lymphoma Kinase Inhibitors Sales by Type
  - 2.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)
  - 2.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Type (2019-2024)
  - 2.3.3 Global Anaplastic Lymphoma Kinase Inhibitors Sale Price by Type (2019-2024)
- 2.4 Anaplastic Lymphoma Kinase Inhibitors Segment by Application
  - 2.4.1 NSCLC
  - 2.4.2 Breast Cancer
  - 2.4.3 Colorectal Cancer
  - 2.4.4 Neuroblastoma
  - 2.4.5 Ovarian Cancer
  - 2.4.6 Others
- 2.5 Anaplastic Lymphoma Kinase Inhibitors Sales by Application

2.5.1 Global Anaplastic Lymphoma Kinase Inhibitors Sale Market Share by Application (2019-2024)

2.5.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue and Market Share by Application (2019-2024)

2.5.3 Global Anaplastic Lymphoma Kinase Inhibitors Sale Price by Application (2019-2024)

### **3 GLOBAL ANAPLASTIC LYMPHOMA KINASE INHIBITORS BY COMPANY**

3.1 Global Anaplastic Lymphoma Kinase Inhibitors Breakdown Data by Company

3.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Annual Sales by Company (2019-2024)

3.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2019-2024)

3.2 Global Anaplastic Lymphoma Kinase Inhibitors Annual Revenue by Company (2019-2024)

3.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Company (2019-2024)

3.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Company (2019-2024)

3.3 Global Anaplastic Lymphoma Kinase Inhibitors Sale Price by Company

3.4 Key Manufacturers Anaplastic Lymphoma Kinase Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Location Distribution

3.4.2 Players Anaplastic Lymphoma Kinase Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR ANAPLASTIC LYMPHOMA KINASE INHIBITORS BY GEOGRAPHIC REGION**

4.1 World Historic Anaplastic Lymphoma Kinase Inhibitors Market Size by Geographic Region (2019-2024)

4.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Anaplastic Lymphoma Kinase Inhibitors Market Size by Country/Region (2019-2024)

4.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Annual Sales by Country/Region (2019-2024)

4.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Annual Revenue by Country/Region (2019-2024)

4.3 Americas Anaplastic Lymphoma Kinase Inhibitors Sales Growth

4.4 APAC Anaplastic Lymphoma Kinase Inhibitors Sales Growth

4.5 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Growth

4.6 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Growth

## **5 AMERICAS**

5.1 Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Country

5.1.1 Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024)

5.1.2 Americas Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024)

5.2 Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Type

5.3 Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Region

6.1.1 APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2019-2024)

6.1.2 APAC Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2019-2024)

6.2 APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Type

6.3 APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

## 6.10 China Taiwan

## 7 EUROPE

### 7.1 Europe Anaplastic Lymphoma Kinase Inhibitors by Country

#### 7.1.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024)

#### 7.1.2 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024)

### 7.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type

### 7.3 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

### 7.8 Russia

## 8 MIDDLE EAST & AFRICA

### 8.1 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors by Country

#### 8.1.1 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024)

#### 8.1.2 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024)

### 8.2 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type

### 8.3 Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application

### 8.4 Egypt

### 8.5 South Africa

### 8.6 Israel

### 8.7 Turkey

### 8.8 GCC Countries

## 9 MARKET DRIVERS, CHALLENGES AND TRENDS

### 9.1 Market Drivers & Growth Opportunities

### 9.2 Market Challenges & Risks

### 9.3 Industry Trends

## 10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Anaplastic Lymphoma Kinase Inhibitors

10.3 Manufacturing Process Analysis of Anaplastic Lymphoma Kinase Inhibitors

10.4 Industry Chain Structure of Anaplastic Lymphoma Kinase Inhibitors

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Anaplastic Lymphoma Kinase Inhibitors Distributors

11.3 Anaplastic Lymphoma Kinase Inhibitors Customer

## **12 WORLD FORECAST REVIEW FOR ANAPLASTIC LYMPHOMA KINASE INHIBITORS BY GEOGRAPHIC REGION**

12.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size Forecast by Region

12.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Forecast by Region (2025-2030)

12.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Anaplastic Lymphoma Kinase Inhibitors Forecast by Type

12.7 Global Anaplastic Lymphoma Kinase Inhibitors Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

13.1 Betta Pharmaceuticals Co., Ltd.

13.1.1 Betta Pharmaceuticals Co., Ltd. Company Information

13.1.2 Betta Pharmaceuticals Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

13.1.3 Betta Pharmaceuticals Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Betta Pharmaceuticals Co., Ltd. Main Business Overview

13.1.5 Betta Pharmaceuticals Co., Ltd. Latest Developments

13.2 Crtierium, Inc.

13.2.1 Crtierium, Inc. Company Information

13.2.2 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

13.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Crtierium, Inc. Main Business Overview

13.2.5 Crtierium, Inc. Latest Developments

13.3 F.Hoffman-La Roche Ltd.

13.3.1 F.Hoffman-La Roche Ltd. Company Information

13.3.2 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

13.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 F.Hoffman-La Roche Ltd. Main Business Overview

13.3.5 F.Hoffman-La Roche Ltd. Latest Developments

13.4 Helsinn Therapeutics

13.4.1 Helsinn Therapeutics Company Information

13.4.2 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

13.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Helsinn Therapeutics Main Business Overview

13.4.5 Helsinn Therapeutics Latest Developments

13.5 Novartis AG.

13.5.1 Novartis AG. Company Information

13.5.2 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

13.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Novartis AG. Main Business Overview

13.5.5 Novartis AG. Latest Developments

13.6 Oncoethix GmbH

13.6.1 Oncoethix GmbH Company Information

13.6.2 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

13.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Oncoethix GmbH Main Business Overview

13.6.5 Oncoethix GmbH Latest Developments

13.7 Pfizer, Inc.

- 13.7.1 Pfizer, Inc. Company Information
- 13.7.2 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications
- 13.7.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.7.4 Pfizer, Inc. Main Business Overview
- 13.7.5 Pfizer, Inc. Latest Developments
- 13.8 Takeda Pharmaceutical Co., Ltd.
- 13.8.1 Takeda Pharmaceutical Co., Ltd. Company Information
- 13.8.2 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications
- 13.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.8.4 Takeda Pharmaceutical Co., Ltd. Main Business Overview
- 13.8.5 Takeda Pharmaceutical Co., Ltd. Latest Developments
- 13.9 Xcovery Holding Company, LLC
- 13.9.1 Xcovery Holding Company, LLC Company Information
- 13.9.2 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications
- 13.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.9.4 Xcovery Holding Company, LLC Main Business Overview
- 13.9.5 Xcovery Holding Company, LLC Latest Developments
- 13.10 Tesaro, Inc.
- 13.10.1 Tesaro, Inc. Company Information
- 13.10.2 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications
- 13.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.10.4 Tesaro, Inc. Main Business Overview
- 13.10.5 Tesaro, Inc. Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Anaplastic Lymphoma Kinase Inhibitors Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Anaplastic Lymphoma Kinase Inhibitors Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Crizotinib

Table 4. Major Players of Ceritinib

Table 5. Major Players of Alectinib Hydrochloride

Table 6. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2024) & (MT)

Table 7. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)

Table 8. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2019-2024) & (\$ million)

Table 9. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2019-2024)

Table 10. Global Anaplastic Lymphoma Kinase Inhibitors Sale Price by Type (2019-2024) & (USD/MT)

Table 11. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2024) & (MT)

Table 12. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2024)

Table 13. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2019-2024)

Table 14. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2019-2024)

Table 15. Global Anaplastic Lymphoma Kinase Inhibitors Sale Price by Application (2019-2024) & (USD/MT)

Table 16. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Company (2019-2024) & (MT)

Table 17. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company (2019-2024)

Table 18. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Company (2019-2024) (\$ Millions)

Table 19. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Company (2019-2024)

Table 20. Global Anaplastic Lymphoma Kinase Inhibitors Sale Price by Company (2019-2024) & (USD/MT)

Table 21. Key Manufacturers Anaplastic Lymphoma Kinase Inhibitors Producing Area Distribution and Sales Area

Table 22. Players Anaplastic Lymphoma Kinase Inhibitors Products Offered

Table 23. Anaplastic Lymphoma Kinase Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Geographic Region (2019-2024) & (MT)

Table 27. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share Geographic Region (2019-2024)

Table 28. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 29. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Geographic Region (2019-2024)

Table 30. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Country/Region (2019-2024) & (MT)

Table 31. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country/Region (2019-2024)

Table 32. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Country/Region (2019-2024) & (\$ millions)

Table 33. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country/Region (2019-2024)

Table 34. Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 35. Americas Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2024)

Table 36. Americas Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (\$ Millions)

Table 37. Americas Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2024)

Table 38. Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2024) & (MT)

Table 39. Americas Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2024) & (MT)

Table 40. APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2019-2024) & (MT)

Table 41. APAC Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2019-2024)

Table 42. APAC Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2019-2024) & (\$ Millions)

Table 43. APAC Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2019-2024)

Table 44. APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2024) & (MT)

Table 45. APAC Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2024) & (MT)

Table 46. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 47. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2024)

Table 48. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (\$ Millions)

Table 49. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2024)

Table 50. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2024) & (MT)

Table 51. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2024) & (MT)

Table 52. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 53. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2024)

Table 54. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (\$ Millions)

Table 55. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2024)

Table 56. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2024) & (MT)

Table 57. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2024) & (MT)

Table 58. Key Market Drivers & Growth Opportunities of Anaplastic Lymphoma Kinase Inhibitors

Table 59. Key Market Challenges & Risks of Anaplastic Lymphoma Kinase Inhibitors

Table 60. Key Industry Trends of Anaplastic Lymphoma Kinase Inhibitors

Table 61. Anaplastic Lymphoma Kinase Inhibitors Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Anaplastic Lymphoma Kinase Inhibitors Distributors List

Table 64. Anaplastic Lymphoma Kinase Inhibitors Customer List

Table 65. Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Region (2025-2030) & (MT)

Table 66. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 67. Americas Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Country (2025-2030) & (MT)

Table 68. Americas Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 69. APAC Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Region (2025-2030) & (MT)

Table 70. APAC Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 71. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Country (2025-2030) & (MT)

Table 72. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 73. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Country (2025-2030) & (MT)

Table 74. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 75. Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Type (2025-2030) & (MT)

Table 76. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Type (2025-2030) & (\$ Millions)

Table 77. Global Anaplastic Lymphoma Kinase Inhibitors Sales Forecast by Application (2025-2030) & (MT)

Table 78. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Forecast by Application (2025-2030) & (\$ Millions)

Table 79. Betta Pharmaceuticals Co., Ltd. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 80. Betta Pharmaceuticals Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 81. Betta Pharmaceuticals Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 82. Betta Pharmaceuticals Co., Ltd. Main Business

Table 83. Betta Pharmaceuticals Co., Ltd. Latest Developments

Table 84. Crtierium, Inc. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 85. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 86. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 87. Crtierium, Inc. Main Business

Table 88. Crtierium, Inc. Latest Developments

Table 89. F.Hoffman-La Roche Ltd. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 90. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 91. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 92. F.Hoffman-La Roche Ltd. Main Business

Table 93. F.Hoffman-La Roche Ltd. Latest Developments

Table 94. Helsinn Therapeutics Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 95. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 96. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 97. Helsinn Therapeutics Main Business

Table 98. Helsinn Therapeutics Latest Developments

Table 99. Novartis AG. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 100. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 101. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Novartis AG. Main Business

Table 103. Novartis AG. Latest Developments

Table 104. Oncoethix GmbH Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 105. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 106. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. Oncoethix GmbH Main Business

Table 108. Oncoethix GmbH Latest Developments

Table 109. Pfizer, Inc. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 110. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 111. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 112. Pfizer, Inc. Main Business

Table 113. Pfizer, Inc. Latest Developments

Table 114. Takeda Pharmaceutical Co., Ltd. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 115. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 116. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 117. Takeda Pharmaceutical Co., Ltd. Main Business

Table 118. Takeda Pharmaceutical Co., Ltd. Latest Developments

Table 119. Xcovery Holding Company, LLC Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 120. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 121. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 122. Xcovery Holding Company, LLC Main Business

Table 123. Xcovery Holding Company, LLC Latest Developments

Table 124. Tesaro, Inc. Basic Information, Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 125. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolios and Specifications

Table 126. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 127. Tesaro, Inc. Main Business

Table 128. Tesaro, Inc. Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of Anaplastic Lymphoma Kinase Inhibitors

Figure 2. Anaplastic Lymphoma Kinase Inhibitors Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Anaplastic Lymphoma Kinase Inhibitors Sales Growth Rate 2019-2030 (MT)

Figure 7. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate 2019-2030 (\$ Millions)

Figure 8. Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2019, 2023 & 2030) & (\$ Millions)

Figure 9. Product Picture of Crizotinib

Figure 10. Product Picture of Ceritinib

Figure 11. Product Picture of Alectinib Hydrochloride

Figure 12. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2023

Figure 13. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2019-2024)

Figure 14. Anaplastic Lymphoma Kinase Inhibitors Consumed in NSCLC

Figure 15. Global Anaplastic Lymphoma Kinase Inhibitors Market: NSCLC (2019-2024) & (MT)

Figure 16. Anaplastic Lymphoma Kinase Inhibitors Consumed in Breast Cancer

Figure 17. Global Anaplastic Lymphoma Kinase Inhibitors Market: Breast Cancer (2019-2024) & (MT)

Figure 18. Anaplastic Lymphoma Kinase Inhibitors Consumed in Colorectal Cancer

Figure 19. Global Anaplastic Lymphoma Kinase Inhibitors Market: Colorectal Cancer (2019-2024) & (MT)

Figure 20. Anaplastic Lymphoma Kinase Inhibitors Consumed in Neuroblastoma

Figure 21. Global Anaplastic Lymphoma Kinase Inhibitors Market: Neuroblastoma (2019-2024) & (MT)

Figure 22. Anaplastic Lymphoma Kinase Inhibitors Consumed in Ovarian Cancer

Figure 23. Global Anaplastic Lymphoma Kinase Inhibitors Market: Ovarian Cancer (2019-2024) & (MT)

Figure 24. Anaplastic Lymphoma Kinase Inhibitors Consumed in Others

Figure 25. Global Anaplastic Lymphoma Kinase Inhibitors Market: Others (2019-2024)

& (MT)

Figure 26. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2023)

Figure 27. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application in 2023

Figure 28. Anaplastic Lymphoma Kinase Inhibitors Sales Market by Company in 2023 (MT)

Figure 29. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Company in 2023

Figure 30. Anaplastic Lymphoma Kinase Inhibitors Revenue Market by Company in 2023 (\$ Million)

Figure 31. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Company in 2023

Figure 32. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Geographic Region (2019-2024)

Figure 33. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Geographic Region in 2023

Figure 34. Americas Anaplastic Lymphoma Kinase Inhibitors Sales 2019-2024 (MT)

Figure 35. Americas Anaplastic Lymphoma Kinase Inhibitors Revenue 2019-2024 (\$ Millions)

Figure 36. APAC Anaplastic Lymphoma Kinase Inhibitors Sales 2019-2024 (MT)

Figure 37. APAC Anaplastic Lymphoma Kinase Inhibitors Revenue 2019-2024 (\$ Millions)

Figure 38. Europe Anaplastic Lymphoma Kinase Inhibitors Sales 2019-2024 (MT)

Figure 39. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue 2019-2024 (\$ Millions)

Figure 40. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales 2019-2024 (MT)

Figure 41. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue 2019-2024 (\$ Millions)

Figure 42. Americas Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country in 2023

Figure 43. Americas Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country in 2023

Figure 44. Americas Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)

Figure 45. Americas Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2024)

Figure 46. United States Anaplastic Lymphoma Kinase Inhibitors Revenue Growth

2019-2024 (\$ Millions)

Figure 47. Canada Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 48. Mexico Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 49. Brazil Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 50. APAC Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region in 2023

Figure 51. APAC Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Regions in 2023

Figure 52. APAC Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)

Figure 53. APAC Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2024)

Figure 54. China Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 55. Japan Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 56. South Korea Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 57. Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 58. India Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 59. Australia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 60. China Taiwan Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 61. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country in 2023

Figure 62. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country in 2023

Figure 63. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)

Figure 64. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2024)

Figure 65. Germany Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 66. France Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 67. UK Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 68. Italy Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 69. Russia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 70. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country in 2023

Figure 71. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country in 2023

Figure 72. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)

Figure 73. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2024)

Figure 74. Egypt Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 75. South Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 76. Israel Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 77. Turkey Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 78. GCC Country Anaplastic Lymphoma Kinase Inhibitors Revenue Growth 2019-2024 (\$ Millions)

Figure 79. Manufacturing Cost Structure Analysis of Anaplastic Lymphoma Kinase Inhibitors in 2023

Figure 80. Manufacturing Process Analysis of Anaplastic Lymphoma Kinase Inhibitors

Figure 81. Industry Chain Structure of Anaplastic Lymphoma Kinase Inhibitors

Figure 82. Channels of Distribution

Figure 83. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Forecast by Region (2025-2030)

Figure 84. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share Forecast by Region (2025-2030)

Figure 85. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share Forecast by Type (2025-2030)

Figure 86. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share Forecast by Type (2025-2030)

Figure 87. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share Forecast by Application (2025-2030)

Figure 88. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global Anaplastic Lymphoma Kinase Inhibitors Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GA005843383EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA005843383EN.html>